This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Natalizumab is being investigated by Biogen Idec Inc. (the sponsor of this research study), in partnership with Elan Pharmaceuticals, Inc., as a possible new treatment for multiple sclerosis (MS). It is hoped that natalizumab may prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. The purpose of this study is to determine whether natalizumab is safe and well-tolerated in individuals with relapsing-remitting MS over an extended period of time. In addition, Biogen Idec will also evaluate whether people make antibodies (a protein that is made sometimes when a person is exposed to a protein that is not normally found in the body) to natalizumab.
Showing the most recent 10 out of 203 publications
